In conjunction with the Bioshares Biotech Summit

Syntara (ASX: SNT)

Syntara Limited is a clinical stage drug development company with a focus on blood related cancers. The company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Syntara is managing three phase 2 clinical studies in diseases of high unmet need with a further two potential phase 1c/2 studies being evaluated for 2024. Lead candidate SNT‐5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. SNT-5505 has already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis.

Imricor (ASX: IMR)

Imricor Medical Systems is a leading developer of innovative MRI-compatible medical devices which can be used to carry out real-time iCMR cardiac ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac ablation procedures.

Chimeric Therapeutics (ASX: CHM)

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. With Chimeric assets are being developed across multiple different disease areas in oncology with 4 current clinical trials in solid tumours and blood cancers in 2024 and multiple clinical catalysts in the next 12-18 months.

PharmAust (ASX: PAA)

PharmAust is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs. MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in cell growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease (MND/ALS).

PainChek (ASX: PCK)

PainChek® is the world’s first regulatory-cleared medical device for the assessment of pain, enabling bestpractice pain management for people living with pain in any environment, from those who cannot reliably selfreport their pain, those who can, and for those whose ability to self-report their pain fluctuates.

KEYNOTE: KP Rx Healthcare Opportunities Fund

KP Rx is specialist healthcare fund, backed by Karst Peak Capital, specialising in healthcare and health tech investments in Australia and New Zealand.

Hashan was the Head of Healthcare at Karst Peak Capital leading the firm’s investments in healthcare. Prior to Karst Peak, Hashan was the Lead Healthcare Analyst at CLSA Australia and the Associate Healthcare Analyst at Macquarie Bank, covering ASX-listed healthcare companies. Preceding his entry into finance, he gained industry experience while working at Eli Lilly Pharmaceuticals. He was also a Lieutenant in the Australian Army Reserves, serving from 2006 to 2014. Hashan holds a Bachelor of Science (Medicine) and a Masters of Commerce (Finance) from the University of New South Wales and is a CFA charterholder. He is based in Sydney.

Investment Panel

Join a range of sector specialists to discuss the latest trends and observations in life sciences.

Panelists include:

Elyse Shapiro – Healthcare Analyst, Canaccord Genuity
Hashan De Silva – Managing Partner, KP Rx
Charles Williams – Managing Director, HB Biotechnology

Cyban (Private)

Cyban’s Brain Pulse Monitor will change the current standard of care by enabling early detection and treatment of brain injury, allowing faster, more relevant treatment decisions, that can lead to life changing patient outcomes and reduce the cost of care for hospitals and payors. Our Brain Pulse Monitor is designed to provide non-invasive, continuous measures of intracranial pressure and brain oxygen saturation that are accurate relative to the existing invasive gold standard.

PYC Therapeutics (ASX: PYC)

PYC Therapeutics is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing RNA therapeutic class. PYC’s drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development. The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials. PYC is progressing two more drug candidates with diseasemodifying potential into human studies in 2024.

Arovella Therapeutics (ASX: ALA)

Arovella Therapeutics is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Additional tumour targeting technologies are anticipated to be used in conjunction with Arovella’s iNKT cell therapy platform.

Nicolab (Private)

1 in 4 people will suffer from stroke in their lifetime. 6 million of the estimated 15 million victims worldwide will die every year. Another 6 million will be permanently disabled for the remainder of their life. To minimize the immense burden of this devastating disease, physicians are faced with the challenging task of quickly evaluating brain images to initiate treatment as soon as possible. Nicolab’s groundbreaking technology enables fast and accurate image analysis that helps physicians in making well-informed decisions. Nicolab developed StrokeViewer® to support the complex process of clinical decision-making in a world where every minute counts.

Radiopharm Theranostics (ASX: RAD)

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, kidney and brain.

Neurotech (ASX: NTI)

Neurotech International is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company commenced Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 CY2022. Neurotech is also conducting additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with Rett Syndrome and Cerebral Palsy.

CurveBeam AI (ASX: CVB)

CurveBeam AI develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company’s flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

Imugene (ASX: IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. The Company’s unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Paradigm Biopharma (ASX: PAR)

Paradigm Biopharmaceuticals is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of iPPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

Aroa Biosurgery (ASX: ARX)

Aroa Biosurgery is a soft-tissue regeneration company committed to ‘unlocking regenerative healing for everybody’. The Company develops, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. The Company’s products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach.

Avecho Biotechnology (ASX: AVE)

Avecho Biotechnology develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Avecho’s major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.

ImmVirX (Private)

ImmVirX is developing novel oncolytic viruses to create powerful new cancer immunotherapy combinations. The first virus is in clinical studies with further agents in pre-clinical development. Its novel oncolytic immunotherapy harnesses the power of viruses to preferentially infect and kill cancer cells and induce local and systemic anti-tumour immune responses.

IMRA

IMRA is a company providing real-life outcomes for surgeons and patients by disrupting, innovating and advancing robotic surgery training and procedures, globally. As well as training based on the latest simulation and VR technologies, the company is creating the world’s most advanced synthetic human organ models for surgical training.

18th Annual Bioshares Biotech Summit

NWR is pleased to partner with Bioshares for the 18th Annual Bioshares Biotech Summit.

When: 12-13 July 2024
Where: Esplanade Hotel, Fremantle, WA

Bioshares is delighted to announce that the 18th Bioshares Biotech Summit will be held at the Esplanade Hotel in Fremantle, Western Australia on the 12-13 July 2024.

Following on from a very successful event in Hobart during 2023 which had a record 200 attendees, the move to Fremantle will provide the opportunity for biotech companies to access new retail and institutional investors in WA, and for biotechs and service providers to build closer links with a very active biotech sector in the state which enjoys strong support from the WA State Government.

Perth has a very active biotech R&D sector which includes the University of WA, the Harry Perkins Institute of Medical Research, the Lions Eye Institute, the Perron Institute for Neurological and Translation Science, and the Telethon Kids Institute. It now has 244 life science companies which has doubled in the last six years.

Successful technologies that were seeded in Perth include Sirtex Medical (sold to China Grand Pharmaceutical in 2018 for $1.9 billion), the ADAPT tissue processing technology that has been implanted in over 35,000 patients from Anteris Technologies, and three drugs (for Duchenne muscular dystrophy) that were discovered at the Perron Institute and licensed to Sarepta Therapeutics and subsequently approved by the FDA.

The Summit is an ideal event for fund managers, stockbrokers and investment bankers active in the sector as well as retail investors who have a committed interest in biotech stocks or are looking to build their knowledge and networks in this space. It remains one of the key, high-level networking events in the sector.